Studies have examined the longitudinal relationships between CSF biomarkers for Alzheimer’s disease (AD) and cognition, but there is discordance in the strength of associations between CSF amyloid-β, t-tau, or p-tau with cognition at different disease stages. This evidence concerns the gene MAPT and Alzheimer disease.